Journal of Medicinal Chemistry 1996-08-16

New low-density lipoprotein receptor upregulators acting via a novel mechanism.

M J Ashton, T J Brown, G Fenton, F Halley, M F Harper, P M Lockey, B Porter, A G Roach, K A Stuttle, N Vicker, R J Walsh

文献索引：J. Med. Chem. 39(17) , 3343-56, (1996)

全文：HTML全文

摘要

The synthesis and biological activity of a new series of benzamides and related compounds that upregulate the expression of the low-density lipoprotein (LDL) receptor in human hepatocytes (HepG2 cells) by a novel mechanism are described. The lead compound, N-[5-[(3-cyclohexylpropionyl)amino]-2-methylphenyl]-4-hydroxybe nzamide (1, RPR102359), increased the expression of the LDL receptors in HepG2 cells by 80% when tested at a concentration of 3 microM. Mevinolin (lovastatin) was found to increase the LDL receptor expression by 70% at the same concentration. In contrast to mevinolin, 1 was found to have no effect on cholesterol biosynthesis in liver homogenates or in HepG2 cells at doses where substantial upregulation of the LDL receptor was observed and thus stimulated LDL receptor expression by a novel mechanism.

相关化合物

  • 4-甲基-3-硝基苯甲...

相关文献：

Structural bases of norovirus RNA dependent RNA polymerase inhibition by novel suramin-related compounds.

2014-01-01

[PLoS ONE 9(3) , e91765, (2014)]

Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.

2012-08-15

[Bioorg. Med. Chem. Lett. 22(16) , 5279-82, (2012)]

N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.

2008-02-01

[Bioorg. Med. Chem. Lett. 18(3) , 1172-6, (2008)]

Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors

2008-01-01

[Bioorg. Med. Chem. Lett. 18 , 4713-5, (2008)]

更多文献...